Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Baricitinib 4 milligram Oral Tablet
Baricitinib 4 milligram · 1 trial · 3 indications
The Oral Disease Severity Scale (ODSS) is a validated tool to assess severity of Oral Lichen Planus. For scoring, the oral cavity is divided into 17 sites and assigned three different scores. A site score, which captures disease extent, a severity score, and an activity score which is obtained by multiplying the site and severity scores. Independently study participants are asked to fill in a numerical rating scale graded from 0-10, with zero meaning no pain and 10 being the worst imaginable pain felt within the last 4 weeks. Scores are added together and range from 0-106, with higher scores meaning more severe disease. Overall change from baseline to week 24 will be reported.
| Arm | Type | Description |
|---|---|---|
| Baricitinib | EXPERIMENTAL | Participants will be asked to take 4mg of baricitinib by mouth daily for up to 24 weeks. |
| Name | Type | Description |
|---|---|---|
| Baricitinib 4 milligram Oral Tablet | DRUG | 4 milligrams once daily |
Inclusion Criteria: 1. Voluntarily signed an Institutional Review Board (IRB) approved informed consent. 2. Be at least ≥ 18 years old. 3. Biopsy proven Oral Lichen Planus (OLP) 4. OLP patients with moderate to severe OLP, and must have failed or not tolerated at least one non-corticosteroid system...
Baricitinib 4 milligram is used for oral lichen planus, a chronic inflammatory condition affecting the mouth. It is being studied as a treatment for this dermatological indication. The drug is currently in Phase 2 clinical development for this use.
Baricitinib 4 milligram targets kinases, as it belongs to the -tinib class of kinase inhibitors. Kinases are enzymes involved in cell signaling and inflammation, and inhibiting them may help reduce the inflammatory response associated with oral lichen planus.
Baricitinib 4 milligram is developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's efficacy and safety in oral lichen planus.
Baricitinib 4 milligram is in Phase 2 clinical development for oral lichen planus. It is an investigational drug and has not been approved by regulatory authorities for this indication. The ongoing trial is a proof-of-concept study to assess its potential efficacy and safety.
Baricitinib 4 milligram is being studied in a Phase 2 clinical trial with the identifier NCT06158113. This trial, titled 'Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study,' is active but not recruiting participants. It is an uncontrolled study enrolling 10 participants in the United States.
Yes, Baricitinib 4 milligram is the same as Baricitinib 4 milligram Oral Tablet. The oral tablet formulation is the form being studied in clinical trials for oral lichen planus. Both names refer to the same drug product.